KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $8.6 billion.

  • Regeneron Pharmaceuticals' Cash & Current Investments fell 451.93% to $8.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.6 billion, marking a year-over-year decrease of 451.93%. This contributed to the annual value of $8.6 billion for FY2025, which is 451.93% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Cash & Current Investments stood at $8.6 billion for Q4 2025, which was down 451.93% from $8.4 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Cash & Current Investments ranged from a high of $10.8 billion in Q4 2023 and a low of $3.5 billion during Q1 2021
  • Over the past 5 years, Regeneron Pharmaceuticals' median Cash & Current Investments value was $8.4 billion (recorded in 2025), while the average stood at $7.9 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Cash & Current Investments skyrocketed by 10122.72% in 2022, and later crashed by 2384.95% in 2025.
  • Regeneron Pharmaceuticals' Cash & Current Investments (Quarter) stood at $5.7 billion in 2021, then soared by 35.96% to $7.7 billion in 2022, then soared by 40.07% to $10.8 billion in 2023, then dropped by 16.9% to $9.0 billion in 2024, then dropped by 4.52% to $8.6 billion in 2025.
  • Its Cash & Current Investments was $8.6 billion in Q4 2025, compared to $8.4 billion in Q3 2025 and $7.5 billion in Q2 2025.